ReviewIndian journal of pharmacology2026
Suzetrigine: A promising analgesic targeting voltage-gated sodium channel.
Review in Indian journal of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractChronic pain management continues to challenge clinicians due to limitations in efficacy and tolerability of current pharmacological therapies. Suzetrigine, a first-in-class selective sodium channel blocker, has emerged as a promising agent for the treatment of neuropathic and chronic pain syndromes. Preclinical and clinical data highlight suzetrigine's unique sodium channel selectivity, reduced central nervous system side effects, and encouraging efficacy signals in neuropathic pain, trigeminal neuralgia, and refractory pain states. Early-phase trials report favorable safety and tolerability compared to conventional sodium channel blockers. Suzetrigine represents a promising new analgesic agent with a novel mechanism of action. Further Phase 3 studies are warranted to establish its role in pain medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.